Colman

Colman is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease. The company leverages advanced structure-based drug design to target G protein-coupled receptor 35 (GPR35), a receptor with significant genetic and functional links to intestinal inflammation. By developing potent and selective GPR35 agonists, Colman aims to provide a new class of oral treatments that can restore intestinal barrier function and reduce inflammation. The company's lead programs are currently in the pre-clinical stage, with a focus on optimizing drug candidates for clinical entry.